AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2020

Feb 25, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2020-02-22

Reporting Person: Schenkein David P (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-22	Common stock	M	2775	—	Acquired	105933	Direct
2020-02-24	Common stock	F	880	$48.66	Disposed	105053	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-22	Restricted stock units	$	M	2775	Disposed		Common stock (2775.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock	79082	Indirect
Common stock	270772	Indirect

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: Shares held by Amy P. Schenkein 2004 Revocable Trust, of which the reporting person's spouse is trustee and beneficiary.

F3: Shares held by David P. Schenkein 2004 Revocable Trust, of which the reporting person is trustee and beneficiary.

F4: The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.